Prihlásiť sa Zaregistrujte sa zadarmo

1 ročný cieľ spoločnosti Acelrx Pharmaceuticals Inc

Aká je hodnota metriky 1 ročný cieľ spoločnosti Acelrx Pharmaceuticals Inc?

Hodnota metriky 1 ročný cieľ spoločnosti Acelrx Pharmaceuticals Inc je $5 +477.91%

Aká je definícia metriky 1 ročný cieľ?

1-ročný cieľ (1-year target) je analytikmi predpokladaná cena akcie za rok od dnešného dňa.

One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.

1 ročný cieľ spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Acelrx Pharmaceuticals Inc

Čomu sa venuje spoločnosť Acelrx Pharmaceuticals Inc?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Firmy s metrikou 1 ročný cieľ podobnou spoločnosti Acelrx Pharmaceuticals Inc